Skip to main content

Norovirus

0
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
2 programs
NoV GI.1/GII.4 Bivalent VLP VaccinePHASE_2Vaccine2 trials
Norovirus GI.1/GII.4 Bivalent VLP VaccinePHASE_2Vaccine1 trial
Active Trials
NCT02669121Completed4,748Est. Jun 2018
NCT02475278Completed50Est. Sep 2015
NCT02661490Completed320Est. Sep 2017
Cocrystal Pharma
Cocrystal PharmaBOTHELL, WA
1 program
CDI-988PHASE_1_21 trial
Active Trials
NCT07198139Recruiting40Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaNoV GI.1/GII.4 Bivalent VLP Vaccine
TakedaNorovirus GI.1/GII.4 Bivalent VLP Vaccine
TakedaNoV GI.1/GII.4 Bivalent VLP Vaccine
Cocrystal PharmaCDI-988

Clinical Trials (4)

Total enrollment: 5,158 patients across 4 trials

NCT02669121TakedaNoV GI.1/GII.4 Bivalent VLP Vaccine

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

Start: Jun 2016Est. completion: Jun 20184,748 patients
Phase 2Completed
NCT02661490TakedaNorovirus GI.1/GII.4 Bivalent VLP Vaccine

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

Start: Feb 2016Est. completion: Sep 2017320 patients
Phase 2Completed
NCT02475278TakedaNoV GI.1/GII.4 Bivalent VLP Vaccine

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

Start: Feb 2015Est. completion: Sep 201550 patients
Phase 2Completed
NCT07198139Cocrystal PharmaCDI-988

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus

Start: Mar 2026Est. completion: Dec 202640 patients
Phase 1/2Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 5,158 patients
Vaccine is the dominant modality (100% of programs)
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.